Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HIPEC plus Paclitaxel and S-1 for Gastric Cancer with Peritoneal Metastasis
NCT05228743Unknown
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Start
- Sep 2020
- Primary completion
- Aug 2023
- Modality
- Cytokines & Interferons, Fc-Fusion Proteins
- Countries
- 1
01
Overview
Randomised, open-label trial of Paclitaxel Micelles for Injection in gastric cancer (GC) (2 arms), sponsored by Tianjin Medical University Cancer Institute and Hospital. Primary endpoint: R0 resection rate at 1 year. Status: unknown.
02
Drugs
Paclitaxel Micelles for Injection
03
Conditions
gastric cancer (GC)
Beyond the preview
Go deeper on NCT05228743.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05228743.